X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.globenewswire.com/news-release/2023/05/30/2678864/0/en/Olema-Oncology-to-Present-at-the-2023-Jefferies-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2022/10/26/2541689/35186/en/Kura-Oncology-Reports-Preliminary-Proof-of-Mechanism-in-Phase-1-2-Clinical-Trial-of-Tipifarnib-Plus-Alpelisib-in-Head-and-Neck-Squamous-Cell-Carcinoma.html
https://www.fiercepharma.com/marketing/novartis-new-rare-disease-drug-vijoice-named-empty-vessel-poised-be-filled
https://www.expresspharma.in/new-novartis-data-show-piqray-effectiveness-across-key-biomarkers-in-patients-with-hr-her2-metastatic-breast-cancer/
https://www.globenewswire.com/news-release/2022/04/06/2417163/0/en/FDA-approves-Novartis-Vijoice-alpelisib-as-first-and-only-treatment-for-select-patients-with-PIK3CA-Related-Overgrowth-Spectrum-PROS.html
https://www.novartis.co.uk/news/media-releases/mhra-approves-licence-extension-novartis%27-targeted-therapy-advanced-breast
https://www.globenewswire.com/news-release/2021/12/16/2353801/35186/en/Kura-Oncology-Doses-First-Patient-in-Phase-1-2-Clinical-Trial-of-Tipifarnib-in-Combination-with-Alpelisib-in-Head-and-Neck-Squamous-Cell-Carcinoma.html
https://www.globenewswire.com/news-release/2021/09/17/2299017/0/en/Novartis-announces-findings-from-a-real-world-study-of-alpelisib-demonstrating-clinical-benefit-in-people-with-PIK3CA-Related-Overgrowth-Spectrum-PROS.html
https://www.globenewswire.com/news-release/2021/07/06/2258117/35186/en/Kura-Oncology-Announces-Clinical-Collaboration-to-Evaluate-Tipifarnib-in-Combination-with-Alpelisib-in-Head-and-Neck-Squamous-Cell-Carcinoma.html
https://www.biospace.com/article/releases/piqray-and-174-is-approved-and-now-available-in-canada-as-the-first-and-only-treatment-specifically-for-patients-with-a-pik3ca-mutation-in-hr-positive-her2-negative-advanced-breast-cancer/
https://www.ema.europa.eu/en/documents/overview/piqray-epar-medicine-overview_en.pdf
http://www.pharmatimes.com/news/eu_regulators_approve_novartis_breast_cancer_combo_1346033
https://www.novartis.com/news/media-releases/novartis-receives-piqray-approval-europe-first-and-only-targeted-medicine-hrher2-advanced-breast-cancer-pik3ca-mutation
http://www.pharmatimes.com/news/new_vaccine_for_ebola_among_chmp_recommendations_1341219
https://www.fiercebiotech.com/special-report/2019-s-new-drug-approvals
https://www.fiercepharma.com/pharma/after-5-blockbuster-nods-2019-novartis-hopes-for-25-more-coming-years
https://www.biopharmadive.com/news/pharming-deal-novartis-cancer-drug-pi3k-immune/561007/
https://www.cnbc.com/2019/08/13/employee-health-benefits-costs-expected-to-rise-5percent-in-2020-new-survey-says.html
https://www.in-pharmatechnologist.com/Article/2019/05/28/Novartis-receives-FDA-approval-for-Piqray
https://in.reuters.com/article/us-novartis-fda/novartis-breast-cancer-treatment-wins-fda-approval-idINKCN1SU2AN
https://www.reuters.com/article/us-esmo-novartis-breast-cancer/novartis-drug-cut-death-risk-by-35-percent-in-gene-mutation-breast-cancer-idUSKCN1MU0M9
https://www.reuters.com/article/us-esmo-novartis-breast-cancer/novartis-drug-cut-death-risk-by-35-percent-in-gene-mutation-breast-cancer-idUSKCN1MU0M9
http://www.pmlive.com/pharma_news/novartis_considers_filings_for_pi3k_drug_in_breast_cancer_1249957
https://www.fiercebiotech.com/biotech/novartis-pi3k-drug-hits-goal-phase-3-breast-cancer-trial-laying-groundwork-for-talks
https://www.reuters.com/article/us-novartis-breast-cancer/novartis-trial-win-lifts-profile-of-new-breast-cancer-drug-idUSKCN1L80PM
https://endpts.com/novartis-just-boasted-of-a-big-phiii-pi3k-success-but-heres-why-we-should-hold-our-applause-for-now/
https://pharmaphorum.com/news/novartis-success-breast-cancer-inhibitor/
Market Place
Share 
